268 related articles for article (PubMed ID: 29764230)
21. Agitation and psychosis in dementia.
Ballard C
Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
[No Abstract] [Full Text] [Related]
22. Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study.
Smeets CHW; Zuidema SU; Hulshof TA; Smalbrugge M; Gerritsen DL; Koopmans RTCM; Luijendijk HJ
J Clin Epidemiol; 2018 Sep; 101():17-27. PubMed ID: 29782995
[TBL] [Abstract][Full Text] [Related]
23. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
24. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.
Yohanna D; Cifu AS
JAMA; 2017 Sep; 318(11):1057-1058. PubMed ID: 28975291
[No Abstract] [Full Text] [Related]
26. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
[TBL] [Abstract][Full Text] [Related]
27. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
[TBL] [Abstract][Full Text] [Related]
28. Treatment of the agitation of late-life psychosis and Alzheimer's disease.
Salzman C
Eur Psychiatry; 2001 Jan; 16 Suppl 1():25s-28s. PubMed ID: 11520475
[TBL] [Abstract][Full Text] [Related]
29. Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates.
Marcinkowska M; Śniecikowska J; Fajkis N; Paśko P; Franczyk W; Kołaczkowski M
CNS Drugs; 2020 Mar; 34(3):243-268. PubMed ID: 32052375
[TBL] [Abstract][Full Text] [Related]
30. Psychosis in Alzheimer's Disease.
Ballard C; Kales HC; Lyketsos C; Aarsland D; Creese B; Mills R; Williams H; Sweet RA
Curr Neurol Neurosci Rep; 2020 Oct; 20(12):57. PubMed ID: 33048274
[TBL] [Abstract][Full Text] [Related]
31. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL
Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087
[TBL] [Abstract][Full Text] [Related]
32. Treatment of acute agitation in psychotic disorders.
Mohr P; Pecenák J; Svestka J; Swingler D; Treuer T
Neuro Endocrinol Lett; 2005 Aug; 26(4):327-35. PubMed ID: 16136016
[TBL] [Abstract][Full Text] [Related]
33. Challenges in estimating mortality risk from antipsychotics in people with Alzheimer's disease.
Carnahan RM
Am J Psychiatry; 2014 Feb; 171(2):227. PubMed ID: 24500460
[No Abstract] [Full Text] [Related]
34. Consequences of antipsychotic medications for the dementia patient.
Devanand DP; Schultz SK
Am J Psychiatry; 2011 Aug; 168(8):767-9. PubMed ID: 21813491
[No Abstract] [Full Text] [Related]
35. An update on the advancements in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Antonsdottir IM
Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
[TBL] [Abstract][Full Text] [Related]
36. Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions.
Wragg RE; Jeste DV
Psychiatr Clin North Am; 1988 Mar; 11(1):195-213. PubMed ID: 2898133
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological treatment of psychotic agitation.
Currier GW; Trenton A
CNS Drugs; 2002; 16(4):219-28. PubMed ID: 11945106
[TBL] [Abstract][Full Text] [Related]
38. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
[TBL] [Abstract][Full Text] [Related]
39. The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.
Miller LJ
Consult Pharm; 2007 Sep; 22(9):754-62. PubMed ID: 18198970
[TBL] [Abstract][Full Text] [Related]
40. To treat or not to treat? Managing acute symptoms in an elderly patient with Alzheimer's disease.
Deegan R; Bailey KP
J Psychosoc Nurs Ment Health Serv; 2001 Oct; 39(10):12-5. PubMed ID: 11697070
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
